Randomized, Open Label, Multicenter Study of Belatacept-based Early Steroid Withdrawal Regimen With Alemtuzumab or rATG Induction Compared to Tacrolimus-based Early Steroid Withdrawal Regimen With rATG Induction in Renal Transplantation

Trial Profile

Randomized, Open Label, Multicenter Study of Belatacept-based Early Steroid Withdrawal Regimen With Alemtuzumab or rATG Induction Compared to Tacrolimus-based Early Steroid Withdrawal Regimen With rATG Induction in Renal Transplantation

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 May 2017

At a glance

  • Drugs Belatacept (Primary) ; Alemtuzumab; Antithymocyte globulin; Methylprednisolone; Mycophenolate mofetil; Mycophenolate sodium; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms BEST
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 May 2017 Results of effects of mTOR inhibition on peripheral blood cells presented at the 2017 American Transplant Congress
    • 15 Dec 2016 Planned primary completion date changed from 1 Nov 2018 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top